To assess the therapeutic potential of these genetic dependencies, we evaluated the sensitivity and specificity of the BRD4 inhibitor JQ1 (Filippakopoulos et al, 2010), the PRMT5 inhibitor GSK591 (Duncan et al, 2016), the TAF1 inhibitor BAY‐299 (Bouché et al, 2017), and the WDR5 inhibitor OICR942 (Grebien et al, 2015) in two MCC cell lines (PeTa, MKL‐1) and in HDFBs. This evidence concerns the gene WDR5 and Merkel cell skin cancer.